The highest retail price limit imposed by the state on drugs has not been adjusted because of the skyrocketing price of Sanqi, and the highest retail prices of drugs such as compound Danshen tablets related to Sanqi remain unchanged. Analysts pointed out that Baiyun Mountain A, Kunming Pharmaceutical, Yunnan Baiyao, Tasly and many other listed companies will face the pressure of soaring costs due to inventory and other reasons.
Wenshan Sanqi Specialty Bureau said that judging from the recent price increase of Sanqi, the prices of some Sanqi varieties have reached or exceeded the highest level in history. If the price of Panax notoginseng continues to rise, two unfavorable factors will be highlighted: First, affected by huge profits, some people and enterprises inside and outside the state will switch to planting Panax notoginseng and blindly expand the planting area of Panax notoginseng; Second, the price of Sanqi products produced by pharmaceutical companies inside and outside the state cannot be increased accordingly, which will inevitably lead to a sharp decline in the acquisition and storage of raw materials of Sanqi pharmaceutical companies. To this end, the National Bureau of Sanqi Specialty Products will try its best to take measures, make corresponding adjustments, regulate the sales price and planting area of Sanqi, and strive to avoid the ups and downs of Sanqi prices.
In this regard, Tan said that the planting of Sanqi before Wenshan was in a disorderly state, and drug dealers simply did not expect that the price of Sanqi would rise so much this year. Because of the long growth cycle of Panax notoginseng, it is inevitable for manufacturers to build a base in Wenshan this year. As for this model, it already exists. For example, Sanjiu Pharmaceutical has its own planting base in Sichuan. The key is how to regulate the market in an orderly manner and stabilize the price of medicinal materials.
Many analysts also believe that it is irrational to intervene in Kangmei Pharmaceutical with Sanqi inventory as the speculation point, and investors are not advised to buy high-valued stocks at this time.
The affected Sanqi planting base
Yunnan is rich in Chinese herbal medicine resources. Since ancient times, medicinal materials such as Panax Notoginseng, Gastrodia elata, Radix Aucklandiae, Radix Angelicae Sinensis and Cordyceps produced in Yunnan have been well-known throughout the country. Due to the drought, the cost of listed companies of Chinese herbal medicines in Yunnan may increase in the next few years. However, according to the reporter's understanding, all pharmaceutical companies still have sufficient stocks, and the short-term and long-term effects are not significant or exist.
The listed pharmaceutical companies in Yunnan are mainly Yunnan Baiyao (000538) and Kunming Pharmaceutical (600422), and Panax notoginseng is only one of the main raw materials of these two companies. At the beginning of the drought at the end of last year, the price of Panax notoginseng in Yunnan was less than 100 yuan per kilogram, and now it is close to 500 yuan.
Wenshan, Yunnan Province is the world's largest exporter of Notoginseng, which is extremely rich in Notoginseng resources. However, the reporter saw in Wenshan that due to waterless irrigation, many rice fields have been abandoned, and green is rarely seen in dry fields. According to the information released by Wenshan, the affected area of Panax notoginseng in this state is about 57,000 mu, accounting for 94.5% of the total planting area, and the affected area is about 280 million mu, accounting for 48.47% of the affected area.
According to the reporter's understanding, Yunnan Baiyao and Kunming Pharmaceutical do not participate in the cultivation of Sanqi, among which Kunming Pharmaceutical mainly buys Sanqi through middlemen; In addition to the order-based production of some varieties of Yunnan Baiyao, the purchase of Sanqi in Wenshan mainly adopts the way of purchasing from local farmers.
Xu Chaoneng, director of Kunming Pharmaceutical, told the reporter: "The company has never encountered water shortage and electricity shortage in its production and operation. In the acquisition of Sanqi, it was through middlemen. Prices have gone up a lot recently. The acquisition is indeed difficult, but we have enough reserves of Sanqi. The price increase of Sanqi will not affect the company's performance for the time being. "
Yunnan Baiyao, which relies more on Sanqi, is relatively cautious. Wei Wu, general manager of the company, told reporters: "At present, the market price of Sanqi has changed greatly, but we have some stocks to cope with it. From the financial point of view, the impact of the price fluctuation of Sanqi on the company cannot be fully evaluated for the time being, but it has little impact at present. However, the long-term impact of the drought on the company may exist. "
It is worth noting that it takes more than three years from sowing to harvesting. The roots of annual Panax notoginseng are usually used as seedlings, and the plants can blossom and bear fruit in the second year. This year's drought has a profound impact on the yield of Panax notoginseng, at least until 20 12.
A local medicinal material industry person in Yunnan told the reporter: "The sharp rise in the price of Sanqi will definitely have an impact on the spot purchase of pharmaceutical companies. This effect depends on the inventory of pharmaceutical companies. But what is certain is that this impact will be realized from this year. "
In the face of the sharp rise in the price of raw materials, whether the price of downstream drugs will also rise has become the focus of attention. Wei Wu told reporters: "It is hard to say whether the drug price will rise, because the price of our products needs the approval of the National Development and Reform Commission. If you need to raise prices, you must first report to the National Development and Reform Commission. "